Search research articles
Contact Us
Filters
Showing results (381-390 of 455) with videos related to
Page
of 46
Sort By:
Clinical Breast Cancer
|
July 19, 2018
Use of Granulocyte-colony Stimulating Factor During Chemotherapy and Its Association With CA27.29 and Circulating Tumor Cells-Results From the SUCCESS A Trial
Philip Hepp, Peter A Fasching, Matthias W Beckmann, et al.
International Journal of Molecular Sciences
|
February 24, 2024
Genetics and beyond: Precision Medicine Real-World Data for Patients with Cervical, Vaginal or Vulvar Cancer in a Tertiary Cancer Center
Fabian B T Kraus, Elena Sultova, Kathrin Heinrich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2010
Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group
Jalid Sehouli, Dirk Stengel, Philipp Harter, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 29, 2011
Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO
Philipp Harter, Jalid Sehouli, Alexander Reuss, et al.
Journal of the National Cancer Institute
|
May 19, 2017
Chemotherapy and Post-traumatic Stress in the Causation of Cognitive Dysfunction in Breast Cancer Patients
Kerstin Hermelink, Markus Bühner, Philipp Sckopke, et al.
Journal of Cancer Research and Clinical Oncology
|
February 28, 2019
Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium
Jun Guan, Silvia Darb-Esfahani, Rolf Richter, et al.
Gynecologic Oncology
|
July 21, 2019
Predicting the course of disease in recurrent vulvar cancer - A subset analysis of the AGO-CaRE-1 study
Linn Woelber, Christine Eulenburg, Jens Kosse, et al.
Frontiers in Oncology
|
June 4, 2026
Real-world data on the clinical impact of molecular tumor boards in high- and low-grade serous ovarian cancer
Fabian B T Kraus, Elena Benkel, Jörg Kumbrink, et al.
The Lancet. Oncology
|
August 14, 2018
Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Radoslav Chekerov, Felix Hilpert, Sven Mahner, et al.
Journal of the National Cancer Institute
|
January 26, 2015
Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study
Sven Mahner, Julia Jueckstock, Felix Hilpert, et al.
Page
of 46
Search research articles
Search
Showing results (381-390 of 455) with videos related to
Sort By:
Page
of 46
Clinical Breast Cancer
|
July 19, 2018
Use of Granulocyte-colony Stimulating Factor During Chemotherapy and Its Association With CA27.29 and Circulating Tumor Cells-Results From the SUCCESS A Trial
Philip Hepp, Peter A Fasching, Matthias W Beckmann, et al.
International Journal of Molecular Sciences
|
February 24, 2024
Genetics and beyond: Precision Medicine Real-World Data for Patients with Cervical, Vaginal or Vulvar Cancer in a Tertiary Cancer Center
Fabian B T Kraus, Elena Sultova, Kathrin Heinrich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2010
Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group
Jalid Sehouli, Dirk Stengel, Philipp Harter, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 29, 2011
Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO
Philipp Harter, Jalid Sehouli, Alexander Reuss, et al.
Journal of the National Cancer Institute
|
May 19, 2017
Chemotherapy and Post-traumatic Stress in the Causation of Cognitive Dysfunction in Breast Cancer Patients
Kerstin Hermelink, Markus Bühner, Philipp Sckopke, et al.
Journal of Cancer Research and Clinical Oncology
|
February 28, 2019
Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium
Jun Guan, Silvia Darb-Esfahani, Rolf Richter, et al.
Gynecologic Oncology
|
July 21, 2019
Predicting the course of disease in recurrent vulvar cancer - A subset analysis of the AGO-CaRE-1 study
Linn Woelber, Christine Eulenburg, Jens Kosse, et al.
Frontiers in Oncology
|
June 4, 2026
Real-world data on the clinical impact of molecular tumor boards in high- and low-grade serous ovarian cancer
Fabian B T Kraus, Elena Benkel, Jörg Kumbrink, et al.
The Lancet. Oncology
|
August 14, 2018
Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Radoslav Chekerov, Felix Hilpert, Sven Mahner, et al.
Journal of the National Cancer Institute
|
January 26, 2015
Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study
Sven Mahner, Julia Jueckstock, Felix Hilpert, et al.
Page
of 46